Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OJP-2028 (Pranidipine) in Uncomplicated Essential Hypertension
NCT00553865Phase 2Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Nov 2007
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pranidipine in essential hypertension (5 arms), sponsored by Jeil Pharmaceutical Co., Ltd. Primary endpoint: Sitting Diastolic Blood Pressure at 8 weeks. Started Nov 2007; status: completed.
02
Drugs
pranidipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00553865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00553865.